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A pproximately 330,000 individuals in Japan cur-rently undergo hemodialysis,  a number that has 
been forecast to increase by 2% annually [The Japan 
Society for Hemodialysis Therapy: Current status of 
hemodialysis therapy and related clinical guideline.  
<http://www. jsdt. or. jp/currentstatus. html.>(accessed 
July,  2016).  End-stage renal disease (ESRD) requiring 
hemodialysis is associated with poor health care out-
comes,  including a 10-fold increase in the risk of hospi-
talization and an expected lifespan shortened by 
17-25% compared to that of the general population [1].  
Fortunately,  although the number of patients undergo-
ing long-term hemodialysis has increased,  the progno-
sis of hemodialysis patients has improved in recent 
years due to advances in areas such as dialysis technol-
ogy,  new drug approaches,  and clinical developments 
[2].  
Despite the well-described outcomes for ESRD in 
community-dwelling individuals,  little is known about 
how long-term hemodialysis contributes to the risks of 
complications and death due to malignancies.  A large 
nationwide study of ESRD patients undergoing dialysis 
in the US revealed a high cumulative incidence of can-
cer,  with > 9% of such patients being diagnosed with 
cancer within 5 years of initiating hemodialysis therapy 
[3].  
Gastric cancer is the second most common malig-
nancy worldwide,  and surgical treatment remains the 
only curative management option [4-6].  Although 
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This retrospective study evaluated the short- and long-term outcomes after surgical management for gastric 
cancer in hemodialysis patients compared to non-dialysis patients.  Twelve hemodialysis patients were com-
pared with a propensity score-matched cohort of 39 gastric cancer patients who had not undergone hemodialy-
sis.  Short- and long-term outcomes along with scores estimating physiological ability and surgical stress were 
evaluated in both groups.  The incidence of postoperative morbidity according to the Clavien-Dindo classifica-
tion was higher in the hemodialysis gastric cancer group than in the non-dialysis gastric cancer group.  The 
5-year overall survival rate in the non-dialysis group was 69.2% after surgical resection for gastric cancer and 
22.2% in the hemodialysis group.  Patients with preoperative risk scores ≥ 0.48 had significantly poorer survival 
outcomes compared to those with preoperative risk scores < 0.48 (5-year survival rate,  83.3% vs. 39.4%,  respec-
tively).  Our analyses suggest that hemodialysis patients undergoing surgery for gastric cancer have a signifi-
cantly poorer postoperative prognosis and an elevated risk of postoperative complications.
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advances in surgical techniques and perioperative man-
agement have made it possible to perform a gastrec-
tomy for gastric cancer safely,  the outcomes for hemo-
dialysis patients undergoing a gastrectomy have been 
unclear.  We conducted the present retrospective study 
to evaluate the short- and long-term outcomes of hemo- 
dialysis patients after surgical management for gastric 
cancer,  compared to non-dialysis gastric cancer 
patients with normal renal function.  We also assessed 
the patients’ immunological status,  consisting of the 
‘inflammation status’ and ‘nutritional condition’,  as this 
is important for the survival of patients with various 
cancers.  For the first time,  the Estimation of Physiologic 
Ability and Surgical Stress (E-PASS) scoring system,  
originally developed for a comparative audit of general 
surgical patients,  was used herein to test whether the 
E-PASS scores can predict long-term outcomes after 
gastrectomy in hemodialysis gastric cancer patients 
[7 , 8].
Patients and Methods
Patients. The diagnosis of gastric cancer was 
made initially based on imaging and then confirmed by 
pathological analysis.  We retrospectively reviewed the 
surgical pathology database of the Kochi Health 
Sciences Center (Kochi,  Japan) to identify the patients 
who underwent a resection for gastric neoplasms from 
March 2005 to December 2014.  The clinical character-
istics evaluated included age,  gender,  parts of the 
tumor,  size of the tumor,  operative procedures,  and 
pathological data.  Our department followed the prog-
nosis of each patient and obtained accurate outcome 
details.  This series included patients with adenocarci-
noma of the stomach and excluded those with gastroin-
testinal a stromal tumor,  carcinoid,  or neuroendocrine 
tumor.
Each surgically resected specimen was macroscopi-
cally examined to determine the maximum tumor 
diameter.  We assessed the location of the gastric cancer,  
the size of the tumor,  stage,  the depth of invasion,  the 
degree of differentiation,  vascular invasion,  lymphatic 
permeation,  and lymph node metastasis according to 
the staging system of the TNM Committee of the 
Japanese classification of gastric cancer (3rd English 
edition) [9 , 10].  This study was approved by the Ethics 
Committee of the Kochi Health Sciences Center,  and all 
patients provided written informed consent for their 
specimens and data to be used and published.  
Assessment. The study data were prospectively 
collected and retrospectively analyzed by a biostatisti-
cian (T. I.).  A propensity score-matched analysis was 
performed to match the hemodialysis patients with the 
control,  non-dialysis gastric cancer patients with nor-
mal renal function based on five values (gender,  age,  
stage,  type of surgery,  and year of operation) that we 
speculated might impact the outcome of radical surgery.  
Surgical complications were determined from the 
patient records during hospitalization and within 30 
days after surgery,  and were then stratified according to 
the Clavien-Dindo (C-D) classification [11].  Overall 
survival was calculated from the date of curative surgery 
for gastric cancer until the date of documentation of 
recurrent disease or death.  The prognostic nutritional 
index (PNI),  a predictor of poor prognosis that is used 
to assess the immune-nutritional status of patients 
undergoing gastrointestinal surgery,  was calculated 
from the complete blood count routinely performed 
before surgery [12-14].
The primary endpoint of this study was overall sur-
vival in patients with gastric cancer after intent-to-cure 
surgical management,  compared between the group of 
hemodialysis patients and the control group of patients 
with normal renal function and therefore without dial-
ysis.  The secondary comparative endpoint was the inci-
dence of postoperative morbidities.  We also assessed 
the correlations between the incidence of postoperative 
complications and the preoperative risk score (PRS),  
the surgical stress score (SSS),  and the comprehensive 
risk score (CRS) of the E-PASS scoring system in both 
groups of patients.
Statistical analysis. Patients alive in October 
2015 were right-censored at the time of follow-up.  We 
compared qualitative variables with the chi-square test 
or Fisher’s test,  whereas quantitative variables were ana-
lyzed using t-tests or a nonparametric test.  Survival data 
were determined using a stratified log-rank test.  All 
tests were two-sided,  with a p-value < 0.05 considered 
significant.  All analyses were performed using SPSS® 
software (SPSS,  Chicago,  IL,  USA).  Overall survival 
and disease-free survival were estimated using the 
Kaplan-Meier method [15].  
Results
Patients. Among the 1,418 patients with gastric 
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cancer who underwent surgical resection at Kochi 
Health Sciences Center during the period described 
above,  only 12 patients (10 males and 2 females) also 
underwent hemodialysis for ESRD.  The mean duration 
of dialysis in these 12 patients was 6.5 years (range 1-33 
years).  Our comparison of these 12 hemodialysis patients 
with gastric cancer to the 39 non-dialysis patients with 
gastric cancer,  matched for gender,  age,  stage,  type of 
surgery,  and year of operation revealed no difference in 
body mass index between the groups.  
Table 1 summarizes the preoperative clinical profiles 
of the patients in both groups.  Clinical symptoms were 
present in 21 of the control patients (53.8%) and in all of 
the hemodialysis patients.  Interestingly,  gastric cancer 
was discovered due to anemia and/or tarry stool in the 
hemodialysis patients,  but in the non-dialysis patients 
the gastric cancer was discovered due to abdominal 
pain and/or during the group examination.  There was 
no significant difference in the prevalence of compli-
cated concurrent or previous diseases between the dial-
ysis and non-dialysis patients.
The baseline preoperative values of all laboratory 
parameters were comparable between the groups,  
except for several parameters related to renal function,  
as expected.  Serum albumin,  hemoglobin,  serum cre-
atinine,  and blood urea nitrogen levels in the non-dial-
ysis patients were significantly preserved compared to 
those in the hemodialysis patients (p < 0.001).  The PNI 
in the non-dialysis group was also significantly higher 
compared to the hemodialysis patients (p < 0.05).  
Moreover,  both the PRS and CRS of the E-PASS scoring 
system were significantly greater in the hemodialysis 
patients compared to the control group (p < 0.05).  
Operative characteristics and oncologic behavior.
Table 2 summarizes the operative characteristics of the 
51 patients who underwent gastric surgery (the 
12 hemodialysis patients + the 39 non-dialysis patients).  
Distal gastrectomy was performed in 34 patients and 
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Table 1　 Preoperative characteristics in patients with gastric cancer
Characteristics GC
(n=39)
HD-GC
(n=12)
Ｐ value
Age, mean (range), years 72 (52-87) 72 (52-87) matching
Gender (male/female) 36/3 10/2 matching
Body mass index 22.2±3.1 21.9±2.9 0.275
Clinical symptoms 21 (53.8) 12 (100.0) 0.004
　Anemia  6 (15.4)  7 (58.3) 0.006
　Abdominal pain 10 (25.6)  0 ( 0.0) 0.092
　Body weight loss  3 ( 7.8)  0 ( 0.0) 1.000
　Tarry stool  1 ( 2.6)  7 (58.3) 0.001
　Group examination 17 (43.6)  0 ( 0.0) 0.004
Concurrent diseases
　Diabetes 14 (35.9)  3 (25.0) 0.728
　Hypertension 13 (33.3)  3 (25.0) 0.730
　Ischemic heart diseases  4 (10.3)  1 ( 8.3) 1.000
　Respiratory diseases  3 ( 7.8)  3 (25.0) 0.134
　Brain infarction  2 ( 5.2)  3 (25.0) 0.078
Preoperative parameters
　Albumin (g/dL)  3.9±0.5  3.4±0.8 0.073
　Hemoglobin (g/dL) 12.2±2.3  9.8±1.5 <0.001
　Creatinine (mg/dL)  0.9±0.2  7.1±3.1 <0.001
　Blood urea nitrogen (mg/dL) 15.4±5.3 36.5±18.5 <0.001
　Hemoglobin A1c (%)  5.7±0.8  5.3±1.6 0.323
　Prognostic nutritional index 47.7±9.9 40.0±8.9 0.023
E-PASS score
　Preoperative risk score 0.49±0.20 0.58±0.28 0.035
　Surgical stress score 0.19±0.14 0.17±0.06 0.087
　Comprehensive risk score 0.33±0.27 0.45±0.28 0.016
Values are mean±SD,  or n (%),  unless otherwise indicated.  GC matched gastric cancer patients,  HD-GC hemodialysis patients with 
gastric cancer,  n number of patients,  E-PASS estimation of physiologic ability and surgical stress.
total gastrectomy in 17 patients.  For all of the patients 
who underwent stomach resection,  the gastrectomy 
consisted of attempted curative resection with regional 
lymphadenectomy.  The operation time and volume of 
blood loss did not differ significantly between the 
non-dialysis and hemodialysis patient groups: opera-
tion time,  225 ± 97 min and 184 ± 41 min; blood loss 
volume,  175 ± 166 mL and 275 ± 224 mL,  respective-
ly; Table 2.  The oncology of the resected tumors also 
did not differ significantly between these groups.
Short-term outcomes. There was no postopera-
tive mortality in this series.  The incidence of postoper-
ative complications (i.e.,  postoperative pneumonia and 
anastomotic leakage) was lower in the non-dialysis 
group than in the hemodialysis group,  although the 
difference was not significant (Table 2).  Overall,  the 
incidence of postoperative morbidity according to the 
C-D classification was significantly higher in the hemo-
dialysis group than in control patients (p = 0.002,  Table 
2).  Notably,  the hemodialysis gastric cancer patients 
required a length of hospitalization that was similar to 
that of the non-dialysis gastric cancer patients.
Long-term outcomes. The causes of death in this 
study are shown in Table 2.  The hemodialysis gastric 
cancer patients had a significantly higher frequency of 
death due to other diseases rather than recurrence of 
gastric cancer compared to the non-dialysis gastric can-
cer patients (p = 0.006),  especially for pneumonia (four 
hemodialysis patients vs. one non-dialysis patient).  The 
length of patient follow-up as of October 2015 ranged 
from 3 to 101 months,  with a median of 60.0 months 
(mean 43.9 months). The overall survival rate at 5 years 
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Table 2　 Operative and postoperative characteristics in patients with gastric cancer
Characteristics GC
(n=39)
HD-GC
(n=12)
Ｐ value
Type of surgery matching
　Distal gastrectomy 26 8
　Total gastrectomy 13 4
Blood loss volume (mL) 175±166 275±224 0.184
Operation time (min) 225±97 184±41 0.072
Pathological ﬁndings
　Size of tumor (cm) 5.0±5.6 5.0±2.9 0.391
　Depth of invasion
　pT1/pT2/pT3/pT4 11/8/4/3 5/4/2/1 0.965
　Lymph node metastases 11 7 0.118
　Vascular invasion 20 8 0.545
　Lymphatic permeation 14 6 0.591
　Liver metastasis 2 1 0.561
　Pathological stage I/Ⅱ/Ⅲ/Ⅳ 14/6/2/4 6/3/2/1 matching
Mortality 0 0 1.000
Morbidities
　Pneumonia 0 2 0.052
　Anastomotic leakage 0 1 0.235
　Delirium 2 0 1.000
Clavien-Dindo grade Ⅲ-V 0 4 0.002
Hospital stay (days) 14±5 15±154 0.313
Causes of death
　Cancer recurrence 9 3 1.000
　Pneumonia 1 4 0.009
　Other malignancies 1＊ 2＊＊ 0.134
　Sudden cardiac arrest 0 1 0.235
　Decrepitude 3 0 1.000
Values are mean±SD or the number of patients.  GC matched gastric cancer patients,  HD-GC hemodialysis patients with gastric cancer,  
n number of patients,  pT1 tumor invasion into lamina propria,  muscularis mucosae,  or submucosa,  pT2 tumor invasion into muscularis 
propria,  pT3 tumor invasion into subserosa,  pT4 tumor perforation of serosa,  or invasion to adjacent organs.  ＊colonic cancer in one 
patient after surgical resection for gastric cancer;  ＊＊lung cancer in 2 patients after surgical resection for gastric cancer.  
in the non-dialysis group was 69.2% after surgical 
resection for gastric cancer,  but only 22.2% in the 
hemodialysis gastric cancer patients (p = 0.004,  Fig. 1).  
Sub-group analyses. Our subgroup analyses of 
postoperative morbidities according to the patients’ 
preoperative baseline characteristics showed no signifi-
cant correlation of nutritional status,  including PNI,  
PRS,  SSS,  and CRS,  to postoperative complications in 
gastrectomized patients,  regardless of the dialysis state.  
Fig. 2 illustrates the relationships among the PRS,  the 
incidence of postoperative complications,  and the grade 
of morbidity according to the C-D classification.  A sig-
nificant positive association was revealed between the 
PRS and the postoperative complications (p < 0.05).
However,  the subgroup analysis of survival accord-
ing to the patients’ preoperative baseline characteristics 
showed a significant difference between the non-dialy-
sis and hemodialysis gastric cancer patients for PRS 
(Spearman product-moment correlation coefficient,  
r = 0.434).  A receiver operating characteristic curve 
analysis indicated that the optimal cut-off value for PRS 
was 0.48,  yielding 87.5% sensitivity and 65.6% specific-
ity for poor prognosis after surgical management 
(p = 0.015).  The patients with a PRS ≥ 0.48 had signifi-
cantly poorer survival outcomes compared to those 
with a PRS < 0.48 (5-year survival rate,  39.4% vs. 
83.3%,  respectively,  p= 0.003,  according to the log-rank 
test; Fig. 3).
Discussion
The overall survival curves were virtually identical in 
this study between hemodialysis patients and patients 
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Fig. 1　 Kaplan-Meier estimates of overall survival in patients 
undergoing hemodialysis (GC-HD) and matched non-dialysis 
patients (GC) after surgery for gastric cancer.
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Fig. 2　 Stacked bar chart showing the proportions of each mor-
bidity score,  according to the PRS.
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Fig. 3　 Kaplan-Meier estimates of overall survival according to 
the preoperative risk score (PRS) of the E-PASS scoring system in 
patients undergoing surgery for gastric cancer.  
with normal renal function after curative surgical treat-
ment for gastric cancer.  At the time of the data evalua-
tion in this study,  the participants included only hemo-
dialysis patients with gastric adenocarcinoma who were 
matched to patients with normal renal function.  Overall 
survival was worse in the hemodialysis patients com-
pared to non-dialysis patients,  and there was a signifi-
cant difference in postoperative morbidity between the 
groups,  according to the C-D classification.  Potentially 
modifiable preoperative variables,  such as PNI,  PRS,  
SSS,  and CRS,  did not differentially affect the compli-
cation rates or the risk of postoperative mortality in the 
hemodialysis patients compared to the non-dialysis 
patients.  However,  our analysis demonstrated that a 
high PRS ( ≥ 0. 48) was significantly associated with a 
poorer survival in gastrectomized patients.
In this series,  excellent curative treatment was 
achieved for the patients with gastric cancer in the 
matched control cohort with normal renal function.  
The long-term prognosis after surgical resection of gas-
tric cancer in the patients undergoing hemodialysis was 
unsatisfactory,  due to a high recurrence rate of gastric 
cancer and to other causes of death,  even when com-
plete resection of the gastric cancer was attained patho-
logically.  Once a complication occurred,  the hemodi-
alysis patients were less likely to survive compared to the 
non-dialysis patients.  Pneumonia,  stroke/cerebrovas-
cular accident,  myocardial infarction,  and unplanned 
intubation appeared to be the most lethal complications 
in hemodialysis patients [16 , 17].
Importantly,  there was no significant difference 
between our 2 patient groups in the incidence of cancer 
recurrence after gastric resection.  However,  the inci-
dence of death due to diseases other than the recurrence 
of gastric cancer after surgical management in the 
hemodialysis group was significantly higher than that in 
the non-dialysis group.  To this end,  our analyses of 
gastric cancer patients with and without hemodialysis 
has identified 2 possible independent risk factors for 
poor prognosis in hemodialysis patients after surgical 
resection for gastric cancer: the postoperative adjuvant 
setting and the systemic inflammation status according 
to the PRS.
The standard adjuvant regimens in Japan for 
advanced gastric cancer are the S-1 single or S-1/CDDP 
combined chemotherapy regimens that were verified in 
the JCOG 9912 and SPIRITS trials [18 , 19].  However,  
no standard adjuvant chemotherapy has been estab-
lished for patients on hemodialysis.  Physicians treating 
such patients must arrange an individualized regimen 
for each patient taking into account the metabolic char-
acteristics of each anti-cancer agent,  although in the 
present study,  none of the hemodialysis patients with 
advanced gastric cancer received adjuvant chemother-
apy after surgical management.
The PRS from the E-PASS scoring system is based on 
the premise that morbidity and mortality rates can be 
correlated with the patient’s physiological risk and the 
surgical stress applied [20].  Interestingly,  our analyses 
suggested that a high PRS was significantly correlated 
with long-term outcomes in gastrectomized patients.  
The correlation between PRS and outcome might there-
fore enable surgeons to predict risks in each individual 
patient before surgery.  The patient’s nutritional intake 
and dietary patterns are also potential determinants of 
health outcomes in individuals undergoing dialysis.  
Postoperative malnutrition after gastrectomy is deemed 
inevitable,  and gastrectomy per se may be a risk for 
mortality [21].  Although the PRS in the present study’s 
patients was not significantly powerful in predicting the 
mortality and morbidity ranges,  if the risk predicted by 
the PRS is high for a patient,  this risk can then be dis-
cussed confidently with both the patient and relatives 
while gaining informed consent.
Our study had some limitations associated with 
errors and biases inherent in a small retrospective study 
design,  where sample sizes are not large enough to per-
form analyses for each patient group.  However,  we 
believe that our report is valuable as a landmark for 
understanding the information and patient care 
required for hemodialysis patients undergoing gastric 
surgery for gastric cancer.
In conclusion,  our findings suggest that hemodialy-
sis patients undergoing surgery for gastric cancer have a 
significantly poorer postoperative prognosis and an 
elevated risk of postoperative complications and death 
compared to their non-dialysis counterparts.  It also 
highlights that the significantly elevated risk of a poor 
outcome and death after surgery deserves an in-depth,  
preoperative discussion with each dialysis patient.
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